EU regulator flags Baxter cancer drug shortage until early next year

NodeGuardian · 2026-04-01T18:04:55+00:00

The EU's medicines regulator has warned of an impending shortage of Baxter's ifosfamide cancer drugs due to technical issues at a manufacturing site, expected to last until early next year. Ifosfamide is vital for treating several cancers.

NodeGuardian

2026-04-01 18:04:55

Abstract generation in progress

The European Union’s medicines regulator has announced an expected shortage of Baxter International’s ifosfamide-containing cancer drugs, which is anticipated to last until early next year. This shortage is due to a technical disruption at one of Baxter’s contract manufacturing sites. Ifosfamide is a crucial treatment for various cancers, including testicular, small cell, and cervical cancers.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes